版本:
中国

Juno Therapeutics Inc (JUNO.O)

JUNO.O ( 纳斯达克 )

44.67USD
01:15 BJT
涨跌 (%)

$-2.74 (-5.78%)
收盘
$47.41
开盘
$47.60
当日最高
$48.62
当日最低
$44.51
成交量
2,183,279
平均成交量
2,734,666
52 周最高
$63.45
52 周最低
$17.52

Chart for

概况

Juno Therapeutics, Inc.是一家专注于重新介入人体免疫系统并治疗癌症的生物制药公司。该公司开发基于嵌合抗原受体(CAR)及T细胞受体(TCR)技术的癌症细胞免疫疗法,通过基因工程技术使T细胞可以识别并杀死癌症细胞。该公司的候选产品JCAR015、JCAR017及JCAR014运用CAR技术靶向CD1... (更多)

概况

Beta: --
市值(百万): $5,412.94
已发行股本(百万): 114.17
股息: --
股息收益率 (%): --

财务指标

BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center

* JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION 全文
12/06 22:11

BRIEF-Juno Therapeutics reports Q3 adjusted loss per share ‍$0.73​

* Juno Therapeutics reports third quarter 2017 financial results 全文
11/02 04:47

UPDATE 2-U.S. FDA approves Gilead cancer gene therapy; price set at $373,000

Oct 18 U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. 全文
10/19 08:11

BRIEF-Juno Therapeutics and Trianni sign licensing agreement for use of Trianni Transgenic Mouse platform

* Trianni and Juno Therapeutics sign licensing agreement for use of Trianni Transgenic Mouse platform 全文
10/18 21:00

BRIEF-Juno Therapeutics prices $250 million follow-on offering

* Juno Therapeutics- Announced pricing of its follow-on public offering of 6.1 million shares of its common stock at a price to public of $41.00 per share Source text for Eikon: Further company coverage: 全文
09/22 09:17

BRIEF-Juno Therapeutics files for offering of common stock aggregate offering price of $225 mln - SEC Filing‍​

* Juno Therapeutics Inc - Files for offering of common stock; aggregate offering price of $225 million - SEC Filing‍​ Source text for Eikon: Further company coverage: 全文
09/21 04:20

RPT-Profit on $475,000 Novartis cancer drug could be a while coming

ZURICH, Aug 31 Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even. 全文
09/01 15:00

Profit on $475,000 Novartis cancer drug could be a while coming

ZURICH, Aug 31 Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even. 全文
09/01 00:25

Novartis gene therapy for leukemia wins U.S. approval

Aug 30 The U.S. Food and Drug Administration (FDA) on Wednesday approved Novartis AG's keenly anticipated leukemia treatment, marking the first gene therapy approval in the United States. 全文
08/30 23:06

BRIEF-Juno Therapeutics qtrly ‍loss per share $0.96

* Juno Therapeutics reports second quarter 2017 financial results 全文
08/04 04:30

收益 vs. 预测